Robotic laparoendoscopic single-site transumbilical partial nephrectomy: Functional and oncologic outcomes at 2 years - Abstract

OBJECTIVE: To assess the functional and oncologic outcomes of robotic laparoendoscopic single site surgery (LESS) partial nephrectomy with a minimum of 2-year follow-up.

MATERIALS AND METHODS: Thirty-nine consecutive patients who had undergone robotic LESS partial nephrectomy were identified with a minimum of 2-year follow-up. Perioperative data were recorded along with functional and oncologic outcomes. Patient's estimated glomerular filtration rate was determined using the Modification of Diet in Renal Disease formula. A univariate analysis was performed using independent samples t test. Data are presented as medians with interquartile range and counts or frequencies with percentages or proportion.

RESULTS: The median age was 51 (45, 59). The median resected tumor size was 3 cm (2, 3.7), and the median operative time was 185 minutes (135, 237). The median estimated blood loss was 150 mL (70, 150), and the median warm ischemia time was 25 minutes (17, 35). The estimated glomerular filtration rate did not change significantly at 24 month follow-up with a mean decrease of 6.4 mL/minute/1.73 m2 (-7.5%, P = .22). Renal cell carcinoma was confirmed in 33 patients (85%) with tumor stage pT1a in 26 patients (78%). There was 1 patient with a positive surgical margin. At a median follow-up of 26 months (24, 32), there was no local recurrence and only 1 distant recurrence was detected.

CONCLUSION: This study appears to be the first to report on intermediate term functional and oncologic outcomes after robotic LESS partial nephrectomy. It has shown comparable results with other minimal invasive surgical options.

Written by:
Tiu A, Shin TY, Kim KH, Lim SK, Han WK, Rha KH.   Are you the author?
Urological Society of Australia and New Zealand, Edgecliff, New South Wales, Australia; Department of Urology, University of Miami, Miller School of Medicine, Miami, FL.

Reference: Urology. 2013 Sep;82(3):595-9.
doi: 10.1016/j.urology.2013.05.010


PubMed Abstract
PMID: 23890663

UroToday.com Renal Cancer Section